We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Commentary on Abstracts #385 and #4384

  • Bruce D. Cheson, MD
Mar 1, 2000
Volume: 
14
Issue: 
3

Unfortunately, even with the high response rates achieved by rituximab relapse is inevitable. With traditional chemotherapeutic regimens, retreatment using the same or similar agents results in lower response rates, and the duration of those responses gets progressively shorter (Gallagher et al: J Clin Oncol 4:1470-1480, 1986).

Davis et al reported on the initial experience with rituximab retreatment at the 1997 ASH meeting (Blood 90:509a [abstract 2269], 1997). The response rate in 60 patients who had previously responded to rituximab was 40%, including 11% CRs. Perhaps most intriguing was that the duration of initial response and time to progression were 9.8 and 12.4 months, respectively, and that these figures rose to 15+ and 16.7+ months, respectively, with retreatment. At the 1999 ASH meeting, Davis et al (abstract #385) presented the updated, final results of this study. Responses were still ongoing in 6 of 23 patients. All of the patients remained CD20-positive, and none developed a human antichimeric antibody (HACA) reaction.

Igarashi et al (abstract #4384) described data from a multicenter Japanese trial in which patients were initially treated with the standard schedule of rituximab and 59% responded. This study included 14 patients with a variety of histologies in favorable (low, low-intermediate) risk groups (according to the International Prognostic Index [Shipp et al: N Engl J Med 329:987-994, 1993]) who had achieved at least stable disease and then showed evidence of progression. The response rate to rituximab retreatment in this study by Igarashi et al was comparable to the experience of Davis et al, with 36% of patients responding, although the median time to progression was 5 months, compared with 8 months following initial treatment.

Nevertheless, these studies clearly show that rituximab can be used to retreat patients, with a reasonable likelihood of clinical benefit. Moreover, retreatment is not accompanied by the myelosuppression usually associated with repeated courses of chemotherapy. However, patients eventually develop resistance to rituximab, and new approaches are needed.

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.